Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo

• Main Authors: Hong-Yan Lin (Author), Hong-Wei Han (Author), Yin-Song Wang (Author), De-Liu He (Author), Wen-Xue Sun (Author), Lu Feng (Author), Zhong-Ling Wen (Author), Min-Kai Yang (Author), Gui-Hua Lu (Author), Xiao-Ming Wang (Author), Jin-Liang Qi (Author), Yong-Hua Yang (Author)
• Format: Book
• Published: BMC, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Tamoxifen (TAM) is a cell type-specific anti-estrogen and is applied to improve the survival of patients with estrogen receptor positive (ER +) breast cancer. However, long-term TAM use can induce serious drug resistance, leading to breast cancer recurrence and death in patients....